DEBN Sp. z o.o.

DEBN (Drug-Eluting Biopsy Needle) is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate. -- Overview -- Prostate cancer is the most common malignancy diagnosed among men in developed countries. The prostate biopsy is a gold standard for detecting this cancer. During this procedure, urologists use a disposable biopsy needle to collect samples of tissue for further analysis. Due to the invasive method of diagnosis patients are advised for oral antibiotics prophylaxis before a biopsy. -- Problem -- The standard biopsy procedure is related with the transfer of intestinal bacterial flora to the blood and prostate. In the recent years, infectious complication rate following prostate biopsies continues to increase. The reason for this phenomenon is the increasing bacterial resistance to the standard oral antimicrobial prophylaxis. Patients undergoing prostate biopsy are exposed to urinary tract infections, prostatitis, and even severe septic complications. Annual treatment cost of prostate biopsy-related complications and insurance payouts is estimated at 1.7 bn USD in the USA and Europe. -- Solution -- Prostate biopsy needle that delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start. This application method allows to use a more effective antibiotic which is not allowed for oral prophylaxis.

• Employees 3
• Founded 2017
• Annual Revenue $6000000